Biologics, Inc. (NC) Announces Collaborative Program Partnership For YERVOY® (Ipilimumab) Patients
Published: Dec 09, 2013
CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc. is pleased to announce the launch of the YERVOY® (ipilimumab) Education & Support (Y.E.S.) Program - designed by Biologics and sponsored by Bristol-Myers Squibb to provide a high-touch support system for patients during their YERVOY therapy. YERVOY is an IV prescription medicine, approved in March 2011, for use in adults to treat melanoma (a kind of skin cancer) that has spread or cannot be removed by surgery. It is not known if YERVOY is safe and effective in patients less than 18 years of age.
Help employers find you! Check out all the jobs and post your resume.